SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental is drawing attention after a Goldman Sachs upgrade to Buy and a move through chart resistance, with traders also pointing to debt reduction, stronger free-cash-flow prospects and bullish call activity. The reaction is mostly optimistic, though some traders question whether the stock can sustain gains as oil prices and Middle East developments remain volatile.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Positive Phase 3 results for Amgens IMDELLTRAIMFINZI combination in first-line small-cell lung cancer are driving attention, with traders highlighting the reported survival benefit and potential to strengthen the drugs growth prospects. The discussion is broadly bullish and also includes anticipation around upcoming earnings and other pipeline updates.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is drawing attention amid a sharp pullback, with traders pointing to its rich valuation and weakness across SaaS stocks; some also worry about competition and growth prospects, while others are looking to buy the dip or favor calls ahead of earnings. The discussion is split between viewing the decline as market-driven and seeing it as a valuation reset.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirm is drawing attention ahead of its upcoming earnings report, with traders weighing expectations for slower growth against continued expansion in revenue and gross merchandise volume. Options activity has leaned toward puts, while the community is split between optimism about the business and concern about the growth outlook, consumer credit and insider selling.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVies quarterly earnings beat and raised outlook, supported by growth in Skyrizi and Rinvoq, are driving attention. Traders are encouraged by the immunology portfolios momentum, while others warn of profit-taking after the stocks strong run-up.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is drawing attention after a sharp volatility-linked move, with traders pointing to a VIX spike and backwardation amid market jitters around oil, interest rates, and geopolitical risk. Some see it as a hedge against a broader selloff, while others caution that the leveraged fund can lose value through decay and may not track volatility moves as expected.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias third-quarter results, including continued LUPKYNIS sales growth and higher full-year revenue guidance, are driving discussion. While some investors view the report as solid execution, others are frustrated that the stock fell despite the results and that management did not hold an earnings call; patent-litigation developments and pipeline updates are also recurring topics.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,559,996,383.70523. The last known price of Dogecoin is 0.07552377 USD and is down -0.48 over the last 24 hours. It is currently trading on 1543 active market(s) with $337,365,256.17 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention for its weak, choppy trading around the 8-cent level, with traders watching nearby support and resistance as broader crypto-market softness weighs on sentiment. Some are buying the dip and holding for a rebound, while others point to persistent declines and worry about further downside.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a 52-week high has intensified buyout speculation, with traders also pointing to bullish call activity and heavy short interest as possible fuel for a squeeze. Others focus on upcoming BRIUMVI sales and guidance, plus the subcutaneous Phase 3 readout, while cautioning that a takeover remains unconfirmed.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQs sharp gain has drawn traders positioning for further Nasdaq weakness, citing tech/AI spending concerns and volatile Iran-war headlines. Some expect more downside and are adding hedges, while others warn that speculation about a U.S.Iran deal and the Strait of Hormuz reopening could lift the broader market; the geopolitical claims remain uncertain.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

First Trust Exchange-Traded Fund VIII - FT Vest U.S. Equity Buffer ETF - October

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

FOCT First Trust Exchange-Traded Fund VIII - FT Cboe Vest U.S. Equity Buffer ETF -October

Fundamentals

Latest FOCT News